IL-29 is elevated in the serum of RA patients and participates in the chemotaxis of peripheral blood neutrophils, inhibits T follicular helper (Tfh) cell differentiation by reducing STAT3/BCL6 activity, and induces RANKL expression in FLSs through the MAPK pathway to participate in bone destruction. Here, STAT3 is linked to rheumatoid arthritis.